Hawthorn (Crataegus)
Hawthorn (Crataegus): What 19 human studies show, including 4 randomized controlled trials – ordered by area of use and strength of evidence.
We evaluated 19 human studies on Hawthorn (Crataegus), including 4 randomised controlled trials and 5 meta-analyses or systematic reviews; the controlled studies include 283 participants in total. As of 11 October 2026.
1. What Is Hawthorn (Crataegus)? Occurrence, Origin and Forms
Hawthorn (Crataegus) is a genus of shrubs and small trees in the rose family (Rosaceae). The species used medicinally in Europe include common hawthorn (Crataegus monogyna) and midland hawthorn (Crataegus laevigata). Its leaves, flowers and fruits have traditionally been used for cardiovascular complaints.
Hawthorn grows in Europe, parts of Asia and North America along woodland edges, in hedgerows and thickets. Many species are also planted as ornamentals and hedging plants.
For use, leaves with flowers are collected at flowering time and fruits in autumn, then dried and processed into extracts, usually dry extracts made with water-alcohol mixtures. Human studies mainly examine standardised dry extracts from leaves with flowers and from fruits.
Forms and Preparations Studied
- Dried leaves with flowers
- Dried fruits
- Dry extract from leaves with flowers
- Dry extract from fruits
- Infusion (tea)
- Liquid extract (tincture)
Not covered on this page:
- Plants containing cardiac glycosides and heart medicines, such as preparations from foxglove (Digitalis purpurea), are separate substances and not hawthorn studies.
- Mixtures of hawthorn with other plants, such as mistletoe (Viscum album) or garlic (Allium sativum), do not count as hawthorn alone.
- Ornamental forms of the genus Crataegus that do not belong to the medicinally used species are not the subject of this page.
- Other thorny shrubs such as blackthorn (Prunus spinosa) are confused with hawthorn but are a different plant.
2. What Does Hawthorn (Crataegus) Do? Results by Area
| Area | Result in controlled studies | Strength of evidence | Studies | Participants |
|---|---|---|---|---|
| Heart failure | mostly no difference | moderate | 1 meta-analyses · 1 controlled · 4 other | 120 |
| Blood pressure | reviews only | low | 1 meta-analyses · 0 controlled · 2 other | 0 |
| Quality of life | mostly no difference | unclear | 0 meta-analyses · 2 controlled · 1 other | 240 |
| Other investigations | mixed | unclear | 0 meta-analyses · 1 controlled · 11 other | 120 |
How to read the table: counted are human studies whose results concern the area. “High” means at least one meta-analysis and two controlled studies showing improvement, or at least three controlled studies of which three quarters show improvement, with at least 300 participants in total. “Moderate” means at least two controlled studies showing improvement, as a majority, or one meta-analysis alongside controlled studies. “Low” means one controlled study showing improvement. Where an area has no controlled study, the strength of evidence is at most “low” (result “reviews only” or “observational data only”). Everything else is “unclear”. A study counts as showing improvement when at least half of its outcomes in this area improved. Reviews of combination products do not count as meta-analyses; results that only describe side effects or shares of users do not count as an effect. The same study is counted only once.
3. What the Studies Show in Detail
Hawthorn (Crataegus) and Heart Failure: Human Studies
In chronic heart failure, a systematic review of hawthorn leaf-with-flower dry extract as a monopreparation showed improvements in maximum performance in the exercise test, exercise tolerance, the rate-pressure product as well as symptoms such as shortness of breath and fatigue compared with placebo, mostly in addition to conventional therapy 1. A more recent randomized controlled trial in addition to standard therapy, by contrast, found no difference in the primary endpoint 6-minute walk distance, only a slightly higher ejection fraction 7. The strength of evidence is moderate: the positive findings come from a review of older studies; the more recent single study found no benefit for symptoms and exercise capacity. Only dry extract from leaves with flowers was studied, not from fruits; dose and standardization differ by preparation and are stated in the study cards. Statements on other preparation forms, on longer-term course and on transferability to patients outside the studied NYHA classes remain open.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Pittler et al. 2008 | meta-analysis · 855 participants | Hawthorn leaf and flower extract monopreparation; vs. Placebo, mostly as adjunct to conventional treatment | Maximal workload: improved (WMD (Watt) 5.35, 95% CI 0.71 to 10.00, P < 0.02, n = 380); Exercise tolerance: improved (WMD (Watt x min) 122.76, 95% CI 32.74 to 212.78, n = 98); Pressure-heart rate product: improved (WMD (mmHg/min) -19.22, 95% CI -30.46 to -7.98, n = 264) |
| 7 Zick et al. 2009 | randomised controlled · 120 participants | Hawthorn extract (leaves with flowers); 450 mg twice daily; 6 months; vs. Placebo added to standard medical therapy | 6 min walk distance: no difference (P = 0.61); left ventricular ejection fraction: unclear (P = 0.04) |
| 10 Ford et al. 2012 | study | Hawthorn extract as adjunct to standard treatment; vs. Standard treatment alone | Cost-effectiveness (QALY): worsened ($85 160.33 per QALY) |
| 12 Soulakhe et al. 2026 | review | Hawthorn (Crataegus spp.), phytochemicals like flavonoids and oligomeric proanthocyanidins; vs. Synthetic cardiotonic agents | Symptom management: improved |
| 17 Wang et al. 2013 | review | Crataegus extracts (Crataegus oxyacantha); vs. Placebo-controlled trials | subjective and objective improvement: improved |
| 19 2006 | review | Hawthorn (leaves, fruit, flowers) | Use for mild heart failure: unclear |
Hawthorn (Crataegus) and Blood Pressure: Human Studies
A meta-analysis of placebo-controlled trials in high blood pressure found lower systolic blood pressure with hawthorn; for diastolic, the difference was not confirmed 2. A randomized controlled trial in heat-exposed shift workers found lower systolic and diastolic values with a hawthorn drink with vitamin C than with salt water; this applies to the mixture, not to hawthorn alone 9. The evidence is low: for hawthorn alone, only the meta-analysis is available, and a separate controlled individual study is lacking. Different forms were studied, whose type, plant part and standardization are not uniformly named; it remains open which preparation and which hawthorn species carry the observed effect.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 2 Szikora et al. 2025 | meta-analysis · 428 participants | Hawthorn (Crataegus spp.); 250-1200 mg/day; 10 weeks to 6 months; vs. Placebo | Systolic blood pressure: improved (MD: -6.65 mmHg; 95% CI [-11.72; 1.59]); Diastolic blood pressure: no difference (MD: -7.19 mmHg; 95% CI [-15.17; 0.79]) |
| 12 Soulakhe et al. 2026 | review | Hawthorn (Crataegus spp.), phytochemicals like flavonoids and oligomeric proanthocyanidins; vs. Synthetic cardiotonic agents | Blood pressure: improved |
| 17 Wang et al. 2013 | review | Crataegus extracts (Crataegus oxyacantha); vs. Placebo-controlled trials | decrease of arterial blood pressure: improved |
Hawthorn (Crataegus) and Quality of Life: Human Studies
In people with diabetes and inflammation of the oral mucosa, oral health-related quality of life improved more with rinses of diluted hawthorn vinegar than with green tea 6. A randomized controlled trial in outpatients with chronic heart failure of NYHA class II–III, by contrast, found no difference in quality of life compared with placebo under a dry extract from leaves with flowers in addition to standard therapy 7. A randomized controlled crossover trial in subjectively stressed but otherwise healthy adults showed, for a combination preparation of Crataegus laevigata fruit extract with Scutellaria baicalensis root extract, magnesium and chromium, an improvement in mood, anxiety and social satisfaction; this statement applies to the mixture, not to hawthorn alone 8. The evidence is unclear: the three controlled trials study different populations, plant parts and preparations, and none is available as a meta-analysis. It remains open whether the findings of the combination preparation are transferable to hawthorn alone.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 6 Demiraǧ et al. 2026 | randomised controlled · 120 participants | Diluted hawthorn vinegar (1 tbsp/10 cc in 40 cc water); Gargle 1 min, 3 times daily, 15-20 min before meals; 14 days; vs. Black mulberry syrup, green tea, control (routine treatment) | Oral health-related quality of life (OHQoL-UK): unclear (p < 0.05) |
| 7 Zick et al. 2009 | randomised controlled · 120 participants | Hawthorn extract (leaves with flowers); 450 mg twice daily; 6 months; vs. Placebo added to standard medical therapy | quality of life: no difference |
| 10 Ford et al. 2012 | study | Hawthorn extract as adjunct to standard treatment; vs. Standard treatment alone | QALY gain: improved (0.02 QALYs) |
Hawthorn (Crataegus): Further Outcomes in Studies
In people with diabetes, inflammation of the oral mucosa decreased more with rinses of diluted hawthorn vinegar than with green tea 6. A combination preparation of hawthorn fruits, Baikal skullcap, magnesium and chromium improved attention and working memory in stressed adults in a placebo-controlled study 8. The strength of evidence is unclear because the findings come from only a few controlled studies with different preparations, populations and comparison groups. A meta-analysis compared Chinese herbal mixtures containing hawthorn for elevated blood lipids with standard medications; its results apply to the mixtures, not to hawthorn alone 3. For hawthorn as a single preparation in cardiovascular diseases, the data are inconsistent 12. An overview lists hawthorn among many medicinal plants used against stress in coronary heart disease 13. Regarding drug interactions and further applications, the data are unclear 1819.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 4 Woerdenbag et al. 2024 | systematic review | Crataegus-containing products, single- and multi-herb preparations | Adverse reactions (VigiBase reports) (1527); Serious single-herb reports (12.6%) |
| 5 Posadzki et al. 2013 | systematic review | Crataegus spp. (hawthorn), form not specified | adverse effects (Minor adverse effects were noted for 31 HMs: ... Crataegus spp.) |
| 6 Demiraǧ et al. 2026 | randomised controlled · 120 participants | Diluted hawthorn vinegar (1 tbsp/10 cc in 40 cc water); Gargle 1 min, 3 times daily, 15-20 min before meals; 14 days; vs. Black mulberry syrup, green tea, control (routine treatment) | Oral mucositis (OAG/ADR): unclear (p < 0.05) |
| 7 Zick et al. 2009 | randomised controlled · 120 participants | Hawthorn extract (leaves with flowers); 450 mg twice daily; 6 months; vs. Placebo added to standard medical therapy | adverse events (P = 0.02) |
| 11 Fei et al. 2026 | review | Medicine-food homology substances, including hawthorn | efficacy as adjuvant therapy in CVD: improved |
| 12 Soulakhe et al. 2026 | review | Hawthorn (Crataegus spp.), phytochemicals like flavonoids and oligomeric proanthocyanidins; vs. Synthetic cardiotonic agents | Exercise tolerance: improved; Endothelial function: improved |
| 13 Azizkhani et al. 2025 | review | Hawthorn (Crataegus spp.) in herbal combinations | Stress reduction and cardiovascular health: improved |
| 14 Nawrot et al. 2022 | review | Hawthorn (Crataegus monogyna and oxyacantha) among plant materials | possibility of reducing post-COVID-19 complications: unclear |
Further studies in this area: 15 16 18 19
4. How Is Hawthorn (Crataegus) Dosed? Preparation, Dose and Duration in Studies
The studies mainly used extract from leaves with flowers, as well as diluted hawthorn vinegar as a mouth rinse, fruit extract in a combination preparation, and a hawthorn drink. Leaf-with-flower extracts and fruit extracts are not interchangeable; species, plant part, dose and standardization differ by preparation and are stated in the study cards. Some studies tested hawthorn only as a component of a mixture with other plants or additives.
| Preparation or form | Dose | Duration | Study |
|---|---|---|---|
| Diluted hawthorn vinegar (1 tbsp/10 cc in 40 cc water) | Gargle 1 min, 3 times daily, 15-20 min before meals | 14 days | 6 |
| Hawthorn extract (leaves with flowers) | 450 mg twice daily | 6 months | 7 |
| Herbal supplement with S. baicalensis, C. laevigata and magnesium/chromium | two tablets as bolus dose, then 15 days | 15 days | 8 |
| 500 mL hawthorn beverage with 278.7 mg flavonoids plus vitamin C tablet | 500 mL beverage with 278.7 mg flavonoids + 130 mg vitamin C daily | 40 days | 9 |
5. Is Hawthorn (Crataegus) Safe? Side Effects in Studies
In a randomized controlled trial in heart failure patients, more adverse events occurred with the leaf-with-flower extract than with placebo, mostly non-cardiac 7. Hawthorn can enhance the effect of anticoagulants, digoxin and blood pressure-lowering drugs 19; a review also mentions a bleeding risk during operations 15. In the placebo studies of the systematic review, side effects were rare, mild and temporary, such as nausea and dizziness 1.
| Study | Reported side effects |
|---|---|
| 1 Pittler et al. 2008 | Infrequent, mild, transient: nausea, dizziness, cardiac and gastrointestinal complaints |
| 2 Szikora et al. 2025 | Safety assessed, no data in abstract |
| 4 Woerdenbag et al. 2024 | Gastrointestinal, cardiac, skin, nervous system and general reactions; 12.6% of single-herb reports serious |
| 5 Posadzki et al. 2013 | Minor adverse effects reported for Crataegus spp. |
| 7 Zick et al. 2009 | More adverse events in hawthorn group (P = 0.02), mostly non-cardiac |
| 8 Dodd et al. 2025 | No serious adverse effects reported |
| 11 Fei et al. 2026 | mild adverse reactions |
| 12 Soulakhe et al. 2026 | Favorable safety profile |
| 13 Azizkhani et al. 2025 | low risk reported |
| 15 Hatfield et al. 2022 | Bleeding risk, including surgical bleeding |
| 16 Kanmanthareddy et al. 2015 | Interactions and adverse effects of herbal medications poorly understood |
| 18 Izzo et al. 2012 | minor risk of adverse effects with hawthorn |
6. What Remains Open: Limits of the Evidence
- Whether hawthorn alleviates symptoms in addition to today's heart failure therapy is open; the more recent study found no benefit 7.
- It is open which preparation and which hawthorn species carry the observed blood pressure effect.
- The transferability of findings on combination preparations to hawthorn alone is unclear.
- Statements on longer-term course and on patients outside the studied NYHA classes are lacking.
- Drug interactions and further uses have hardly been studied.
7. Bottom Line: What Is Established About Hawthorn (Crataegus)
Hawthorn is best studied as a dry extract from leaves with flowers. The evidence is moderate for heart failure, otherwise low or unclear, and relies mainly on review articles.
The data are inconsistent: a systematic review of older placebo studies found better exercise tolerance and fewer symptoms in heart failure 1. A more recent randomized controlled trial in addition to standard therapy, by contrast, showed no benefit for walking distance and quality of life, but more adverse events than placebo 7. Further positive findings concern combination preparations and do not apply to hawthorn alone 89. The data on tolerability, interactions and further applications are limited 1819.
Frequently Asked Questions
How well has Hawthorn (Crataegus) been studied in humans?
We evaluated 19 human studies on Hawthorn (Crataegus), including 4 randomised controlled trials and 5 meta-analyses or systematic reviews; the controlled studies include 283 participants in total. As of 11 October 2026.
Does Hawthorn (Crataegus) help with heart failure? What the studies show
Does Hawthorn (Crataegus) help with blood pressure? What the studies show
Does Hawthorn (Crataegus) help with quality of life? What the studies show
What is hawthorn and which plant parts are used?
Hawthorn (Crataegus) is a genus of shrubs and small trees from the rose family. Medicinally used are mainly the common hawthorn (Crataegus monogyna) and the midland hawthorn (Crataegus laevigata). Leaves with flowers and fruits are used, traditionally for cardiovascular complaints.
Do human studies show an effect in heart failure?
A systematic review of placebo-controlled trials found better exercise tolerance and less shortness of breath and fatigue 1. A more recent randomized controlled trial in addition to standard therapy, by contrast, found no difference in the 6-minute walking distance 7. Only leaf-with-flower extract was studied, not fruit extract.
How does hawthorn affect blood pressure?
A meta-analysis of placebo-controlled trials found a lower systolic blood pressure with hawthorn; for diastolic blood pressure, the difference was not confirmed 2. In heat-exposed shift workers, blood pressure fell more with a hawthorn drink with vitamin C than with salt water; this applies to the mixture 9. Which preparation and which hawthorn species carry the effect remains open.
Which side effects and interactions have been reported?
In a randomized controlled trial in heart failure patients, more adverse events occurred with the leaf-with-flower extract than with placebo, mostly non-cardiac 7. Hawthorn can enhance the effect of anticoagulants, digoxin and blood pressure-lowering drugs 19; a review also mentions a bleeding risk during operations 15.
Do the results also apply to hawthorn in combination preparations?
Sources
- 1Pittler MH, Guo R, Ernst E · 2008
- 2Szikora Z, Mátyus RO, Szabó BV, Csupor D, Tóth B · 2025
- 3Zhou X, Chen C, Gao Z, Qian Z, Miao J · 2024
- 4Woerdenbag HJ, Ursidae M, Ekhart C, Schmidt M, Vitalone A, van Hunsel FPAM · 2024
- 5Posadzki P, Watson LK, Ernst E · 2013
- 6
- 7Zick SM, Vautaw BM, Gillespie B, Aaronson KD · 2009
- 8Dodd F, Weishaupt R, Katumba PKM, Elcoate R, Wightman E · 2025
- 9
- 10
- 11Fei S, Rao Y, Lai J, Zhang B, Ma H, Ma X et al. · 2026
- 12Soulakhe N, Singhai H, Rathee S, Soni S, Patil UK · 2026
- 13Azizkhani L, Jahangiri S, Dehestani SM, Hojati H, Ebrahimi Y · 2025
- 14Nawrot J, Gornowicz-Porowska J, Budzianowski J, Nowak G, Schroeder G, Kurczewska J · 2022
- 15Hatfield J, Saad S, Housewright C · 2022
- 16Kanmanthareddy A, Reddy M, Ponnaganti G, Sanjani HP, Koripalli S, Adabala N et al. · 2015
- 17Wang J, Xiong X, Feng B · 2013
- 18
- 19Hawthorn· 2006
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.